 The following is a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks Biotech stocks that hit 52-week highs Feb. 5. Alector Inc NASDAQ: ALEC announced granting of Fast Track Designation to its AL101 for the treatment of patients with frontotemporal dementia Arvinas Inc NASDAQ: ARVN Ascendis Pharma AS NASDAQ: ASND Biogen Inc NASDAQ: BIIB won patent challenge on multiple sclerosis drug Tecfidera BioXcel Therapeutics Inc NASDAQ: BTAI announced FDA clearance of IND for BXCL501 to treat opioid withdrawal symptoms ChemoCentryx Inc NASDAQ: CCXI Eli Lilly And Co NYSE: LLY Insmed Incorporated NASDAQ: INSM Halozyme Therapeutics, Inc. NASDAQ: HALO Insulet Corporation NASDAQ: PODD Johnson Johnson NYSE: JNJ Masimo Corporation NASDAQ: MASI Medpace Holdings Inc NASDAQ: MEDP Molecular Templates Inc NASDAQ: MTEM Novo Nordisk AS NYSE: NVO reacted to quarterly results Profound Medical Corp NASDAQ: PROF announced retirement of bank debt ahead of schedule PTC Therapeutics, Inc NASDAQ: PTCT Quest Diagnostics Inc NYSE: DGX Reata Pharmaceuticals Inc NASDAQ: RETA Repligen Corporation NASDAQ: RGEN ResMed Inc. NYSE: RMD Revance Therapeutics Inc NASDAQ: RVNC Theravance Biopharma Inc NASDAQ: TBPH Vertex Pharmaceuticals Incorporated NASDAQ: VRTX ZEALAND PHARMAS ADR NASDAQ: ZEAL Down In The Dumps Biotech stocks that hit 52-week lows Feb. 5. Endologix, Inc. NASDAQ: ELGX Salarius Pharmaceuticals Inc NASDAQ: SLRX Spring Bank Pharmaceuticals Inc NASDAQ: SBPH See also: The Week Ahead In Biotech: Merck, Bristol-Myers Earnings, Conference Presentations In Focus Stocks In Focus Sanofis Multiple Sclerosis Drug Aces Midstage Trial; Q4 Sales, Net Income Rise Sanofi SA NASDAQ: SNY said a Phase 2b study that evaluated its investigational BTK inhibitor SAR442168 for multiple sclerosis met the primary endpoint, ... 